Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Induces
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Denmark: Dapson; France: Disulone; Germany: Dapson-Fatol; Greece: Sulfona; Malta: Dapsone; Netherlands: Dapson; Portugal: Sulfona; Romania: Disulone; Slovakia: Disulone; UK: Dapsone.

North America

USA: Aczone, Dapsone; Canada: Dapsone.

Latin America

Argentina: D.A.P.S.; Mexico: Dapsoderm-X.


Japan: Lectisol, Protogen.

Drug combinations


Dapsone: C~12~H~12~N~2~O~2~S. Mw: 248.30. 4,4′-Sulfonyldianiline. CAS-80-08-0 (1963).

Pharmacologic Category

Miscellaneous Antimycobacterials. Skin and Mucous Membrane Agents, Miscellaneous. (ATC-Code: D10AX05; J04BA02).

Mechanism of action

Synthetic sulfone, antimycobacterial and antiprotozoal agent. Competitive antagonist of PABA (p-aminobenzoic acid) and inhibits folic acid synthesis in susceptible organisms. Mechanism of action in the treatment of dermatitis herpetiformis is unknown (may act as an immunomodulator).

Therapeutic use

Treatment of leprosy (used in rifampin-based multiple-drug regimens), and dermatitis herpetiformis.

Pregnancy and lactiation implications

Should be used during pregnancy only when clearly needed. In leprosy, some clinicians consider that benefits of maintaining dapsone therapy during pregnancy outweigh potential risks to fetus. Should not be used in nursing women.

Unlabeled use

Prophylaxis of toxoplasmosis in severely-immunocompromised patients. Used in conjunction with trimethoprim for the treatment of initial episodes of Pneumocystis jiroveci (formerly P. carinii) pneumonia in adults with acquired immunodeficiency syndrome.


Contraindicated in patients who are hypersensitive to the drug or dapsone derivatives such as sulfoxone sodium.

Warnings and precautions

Hemolysis may occur (should not be administered to patients with severe anemia and should be used with caution in G6PD deficiency, methemoglobin reductase deficiency, hemoglobin M, and in patients who are exposed to other drugs or agents capable of inducing hemolysis or who have conditions associated with hemolysis (e.g. certain infections, diabetic ketosis)). Leprosy reactional states (reversal reactions, type 1, and erythema nodosum leprosum reactions, type 2) generally occur during therapy of leprosy. Dermatologic reactions (rarely) or sulfonamide allergy. Prolonged use may result in fungal or bacterial superinfection. Toxic hepatitis and cholestatic jaundice reported.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart